

## NEW SALES REPORTING FORMAT



\$MM

	2011				
	Q1	Q2	Q3	Q4	Full Year
<b>PHARMACEUTICAL SEGMENT <sup>(1)</sup></b>					
<b>IMMUNOLOGY</b>					
US	1,436	1,524	1,390	1,401	5,751
Intl	144	131	377	395	1,047
WW	1,580	1,655	1,767	1,796	6,798
<b>REMICADE</b>					
US	788	836	876	776	3,276
US Exports <sup>(2)</sup>	490	527	343	437	1,797
Intl	7	8	189	215	419
WW	1,285	1,371	1,408	1,428	5,492
<b>SIMPONI</b>					
US	53	61	59	62	235
Intl	42	6	70	57	175
WW	95	67	129	119	410
<b>STELARA</b>					
US	105	100	112	126	443
Intl	61	76	77	81	295
WW	166	176	189	207	738
<b>OTHER IMMUNOLOGY</b>					
US	-	-	-	-	-
Intl	34	41	41	42	158
WW	34	41	41	42	158
<b>INFECTIOUS DISEASES</b>					
US	624	351	216	210	1,401
Intl	307	477	498	506	1,788
WW	931	828	714	716	3,189
<b>INTELENCE</b>					
US	38	38	42	45	163
Intl	31	41	41	38	151
WW	69	79	83	83	314
<b>LEVAQUIN/FLOXIN</b>					
US	422	149	14	(6)	579
Intl	12	10	11	11	44
WW	434	159	25	5	623
<b>PREZISTA</b>					
US	126	128	132	143	529
Intl	140	185	184	173	682
WW	266	313	316	316	1,211
<b>OTHER INFECTIOUS DISEASES</b>					
US	38	36	28	28	130
Intl	124	241	262	284	911
WW	162	277	290	312	1,041

See footnotes at end of schedule

2011

**PHARMACEUTICAL SEGMENT (cont.)****NEUROSCIENCE**

US	688	684	634	611	2,617
Intl	1,057	1,096	1,050	1,128	4,331
WW	1,745	1,780	1,684	1,739	6,948

**CONCERTA/METHYLPHENIDATE**

US	254	234	179	155	822
Intl	108	115	104	119	446
WW	362	349	283	274	1,268

**INVEGA**

US	69	76	74	66	285
Intl	51	52	52	59	214
WW	120	128	126	125	499

**INVEGA SUSTENNA**

US	65	70	85	99	319
Intl	-	7	16	36	59
WW	65	77	101	135	378

**RISPERDAL CONSTA**

US	114	110	111	108	443
Intl	290	294	279	277	1,140
WW	404	404	390	385	1,583

**OTHER NEUROSCIENCE**

US	186	194	185	183	748
Intl	608	628	599	637	2,472
WW	794	822	784	820	3,220

**ONCOLOGY**

US	64	93	79	95	331
Intl	375	459	415	468	1,717
WW	439	552	494	563	2,048

**DOXIL/CAELYX**

US	64	56	10	10	140
Intl	75	82	76	29	262
WW	139	138	86	39	402

**VELCADE**

US	-	-	-	-	-
Intl	280	347	295	352	1,274
WW	280	347	295	352	1,274

**ZYTIGA**

US	-	37	69	85	191
Intl	5	12	26	67	110
WW	5	49	95	152	301

**OTHER ONCOLOGY**

US	-	-	-	-	-
Intl	15	18	18	20	71
WW	15	18	18	20	71

**TOTAL OTHER**

US	579	587	550	570	2,286
Intl	785	831	773	710	3,099
WW	1,364	1,418	1,323	1,280	5,385

**ACIPHEX/PARIET**

US	109	101	94	110	414
Intl	130	146	141	144	561
WW	239	247	235	254	975

**PROCRI/EPREX**

US	190	257	176	191	814
Intl	207	218	207	177	809
WW	397	475	383	368	1,623

**OTHER**

US	280	229	280	269	1,058
Intl	448	467	425	389	1,729
WW	728	696	705	658	2,787

**TOTAL PHARMACEUTICAL**

US	3,391	3,239	2,869	2,887	12,386
Intl	2,668	2,994	3,113	3,207	11,982
WW	6,059	6,233	5,982	6,094	24,368

See footnotes at end of schedule

	2011				
	Q1	Q2	Q3	Q4	Full Year
<b><u>MEDICAL DEVICES AND DIAGNOSTICS</u></b> <sup>(1)</sup>					
<b><u>CARDIOVASCULAR CARE</u></b>					
US	242	210	198	191	841
Intl	393	377	328	349	1,447
WW	635	587	526	540	2,288
<b><u>DIABETES CARE</u></b>					
US	311	333	338	330	1,312
Intl	326	348	326	340	1,340
WW	637	681	664	670	2,652
<b><u>DIAGNOSTICS</u></b> <sup>(3)</sup>					
US	265	281	265	280	1,091
Intl	256	269	274	274	1,073
WW	521	550	539	554	2,164
<b><u>GENERAL SURGERY</u></b> <sup>(4)</sup>					
US	596	621	609	639	2,465
Intl	1,025	1,079	1,013	1,055	4,172
WW	1,621	1,700	1,622	1,694	6,637
<b><u>INFECTION PREVENTION/OTHER</u></b> <sup>(5)</sup>					
US	95	98	90	94	377
Intl	121	134	130	144	529
WW	216	232	220	238	906
<b><u>ORTHOPAEDICS</u></b> <sup>(6)</sup>					
US	811	770	737	775	3,093
Intl	692	699	647	678	2,716
WW	1,503	1,469	1,384	1,453	5,809
<b><u>SPECIALTY SURGERY</u></b> <sup>(7)</sup>					
US	296	311	292	327	1,226
Intl	281	309	284	307	1,181
WW	577	620	576	634	2,407
<b><u>VISION CARE</u></b>					
US	256	245	251	214	966
Intl	466	487	501	496	1,950
WW	722	732	752	710	2,916
<b><u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u></b>					
US	2,872	2,869	2,780	2,850	11,371
Intl	3,560	3,702	3,503	3,643	14,408
WW	6,432	6,571	6,283	6,493	25,779

(1) Select areas (unaudited)

(2) Reported as U.S. sales

(3) Previously Ortho-Clinical Diagnostics

(4) General Surgery includes the endo-mechanical, hernia, sutures and women's health businesses previously part of Ethicon and Ethicon Endo-Surgery

(5) Infection Prevention/Other includes the Advanced Sterilization Products business previously part of Ethicon Endo-Surgery

(6) Previously DePuy

(7) Specialty Surgery includes the Acclarent, biosurgery, energy, Mentor and SterilMed businesses previously part of Ethicon and Ethicon Endo-Surgery